Phase II trial of dacomitinib in patients with HER2-positive gastric cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II trial of dacomitinib in patients with HER2-positive gastric cancer
Authors
Keywords
HER2, Gastric cancer, Dacomitinib, HER2 ECD, Soluble E-cadherin
Journal
Gastric Cancer
Volume 19, Issue 4, Pages 1095-1103
Publisher
Springer Nature
Online
2015-11-18
DOI
10.1007/s10120-015-0567-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
- (2015) C.-Y. Ock et al. CLINICAL CANCER RESEARCH
- Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
- (2015) Sylvie Lorenzen et al. EUROPEAN JOURNAL OF CANCER
- Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions
- (2014) Solange Peters et al. CANCER TREATMENT REVIEWS
- Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer
- (2014) Marcelo Garrido et al. Expert Review of Anticancer Therapy
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of serum HER2-ECD levels in patients with gastric cancer
- (2014) Katsunobu Oyama et al. JOURNAL OF GASTROENTEROLOGY
- Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors
- (2012) Toshiaki Takahashi et al. INVESTIGATIONAL NEW DRUGS
- Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2012) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
- (2012) O. Kalous et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells
- (2011) Magdalena M. Grabowska et al. CELLULAR SIGNALLING
- Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
- (2011) P. A. Janne et al. CLINICAL CANCER RESEARCH
- Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment
- (2011) Judith Maresch et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Soluble E-cadherin promotes cell survival by activating epidermal growth factor receptor☆
- (2011) Landon J. Inge et al. EXPERIMENTAL CELL RESEARCH
- Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
- (2011) H.-J. Nam et al. MOLECULAR CANCER THERAPEUTICS
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Non–Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab
- (2010) Ronan J. Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer
- (2009) Siân Lennon et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
- The Ectodomain Shedding of E-cadherin by ADAM15 Supports ErbB Receptor Activation
- (2008) Abdo J. Najy et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started